Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals
February 27 2024 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, announced the completion of more than 1,000 successful
cases each at three hospitals utilizing the Senhance® Surgical
System: Klaipeda University Hospital (Lithuania), Presidential
Clinic Astana (Kazakhstan), and Evangelisches Krankenhaus Wesel
GmbH (Germany).
"We're thrilled to reach the significant milestone of 1,000
successful Senhance cases at each of these reputable hospitals.
This achievement underscores the growing acceptance and confidence
in our Senhance Surgical System," remarked Anthony Fernando,
President and CEO of Asensus Surgical. "It's a testament to our
unwavering dedication to advancing surgical capabilities and
ultimately improving patient outcomes."
The Senhance Surgical System is designed to
increase surgeon control and reduce variability through Augmented
Intelligence and deep learning capabilities.
About Asensus Surgical, Inc.
Asensus Surgical is revolutionizing surgery with the first
intra-operative Augmented Intelligence technology approved for use
in operating rooms around the world. Recognized as an award-winning
leader in digital technology, Asensus is committed to making
surgery more accessible and predictable while delivering
consistently superior outcomes. The Company’s novel approach to
digitizing laparoscopy has led to system placements globally. Led
by engineers, medical professionals, and industry luminaries,
Asensus is powered by human ingenuity and driven by collaboration.
To learn more about the Senhance® Surgical System and the new LUNA™
System, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc/
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to three
hospitals utilizing the Senhance Surgical System each completing
1,000 cases. These statements regarding our future plans and goals
constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
successful completion of 1,000 cases at each of the three hospitals
will continue the growing acceptance and confidence in the Senhance
Surgical System. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2022,
filed with the SEC on March 2, 2023 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/330b7b98-2850-43cc-95bc-fd154df9e0fd
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2023 to Apr 2024